Mizuho's Jared Holz on Novo Nordisk: There's not much upside near-term

Jared Holz, Mizuho healthcare strategist, joins 'Squawk Box' to discuss Novo Nordisk's quarterly earnings results, which hiked its outlook for 2023 after reporting a 30% increase in sales for the first half of the year, powered by strong demand for its weight loss drugs, and more.